Maximal testosterone suppression in prostate cancer - Free vs total testosterone

Kyle O. Rove, E. David Crawford, Massimo Perachino, Juan Morote, Laurence Klotz, Paul H. Lange, Gerald L. Andriole, Alvin M. Matsumoto, Samir S. Taneja, Mario A. Eisenberger, Leonardo O. Reis

    Research output: Contribution to journalArticle

    Abstract

    Testosterone remains a key target in the treatment of advanced prostate cancer. The relationship of free testosterone to prostate cancer treatment and outcomes remains largely unexplored. A consensus of prostate cancer experts was convened in 2013 to review current knowledge surrounding relationship of total and free testosterone to prostate cancer, discuss the free hormone hypothesis, and highlight future avenues for therapeutics. Free testosterone may better reflect prostate cancer tissue androgen levels than serum total testosterone concentration. Free testosterone deserves more research regarding its relation to clinical outcomes.

    Original languageEnglish (US)
    Pages (from-to)1217-1222
    Number of pages6
    JournalUrology
    Volume83
    Issue number6
    DOIs
    StatePublished - Jun 2014

    ASJC Scopus subject areas

    • Urology

    Fingerprint Dive into the research topics of 'Maximal testosterone suppression in prostate cancer - Free vs total testosterone'. Together they form a unique fingerprint.

  • Cite this

    Rove, K. O., Crawford, E. D., Perachino, M., Morote, J., Klotz, L., Lange, P. H., Andriole, G. L., Matsumoto, A. M., Taneja, S. S., Eisenberger, M. A., & Reis, L. O. (2014). Maximal testosterone suppression in prostate cancer - Free vs total testosterone. Urology, 83(6), 1217-1222. https://doi.org/10.1016/j.urology.2014.02.001